Trial intelligence / Profile preview

Phase 3 study of subcutaneous BI 456906 versus placebo in overweight or obesity without type 2 diabetes

CTR20234044Phase 3Completed

Sponsor
——/ 勃林格殷格翰(中国)投资有限公司
Start
Feb 2024
Modality
Peptides
Countries
1
01

Overview

A Phase 3 trial of survodutide in obesity, Overweight, sponsored by ——/ 勃林格殷格翰(中国)投资有限公司. Started Feb 2024; status: completed.

02

Drugs

03

Conditions

obesityOverweight

Beyond the preview

Go deeper on CTR20234044.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20234044.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call